Infant formula maker Abbott says it’s reached an agreement with U.S. health officials to restart production at its largest domestic factory, a key step toward easing a nationwide shortage.
Abbott did not immediately detail the terms of the agreement reached with the Food and Drug Administration, which has been investigating safety problems at the Michigan facility.
The consent decree is a binding legal agreement between the company and the federal government.
After production resumes, Abbott has said it will take at least eight weeks to begin shipping new product to stores.
The Biden administration has come under intense pressure over the last week to do more to ease the shortage of formula.
(Copyright 2022 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed without permission.)
We’ve agreed to enter into a consent decree – a legal agreement – with the FDA for our Sturgis, Mich., plant, a major step toward reopening our facility and helping to ease the infant formula shortage.
— Abbott (@AbbottNews) May 16, 2022
Read more here: https://t.co/NiUfVJEKWy pic.twitter.com/jr2DXwOUk7
